FY2025 EPS Estimate for Gossamer Bio Increased by Analyst

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Gossamer Bio in a research report issued to clients and investors on Monday, March 24th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will earn ($0.70) per share for the year, up from their prior estimate of ($0.72). The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). The business had revenue of $9.38 million for the quarter, compared to the consensus estimate of $7.02 million.

Other equities analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a research note on Tuesday, March 18th. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Friday, March 14th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Gossamer Bio currently has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $1.28 on Wednesday. The firm has a fifty day simple moving average of $1.18 and a two-hundred day simple moving average of $0.99. The firm has a market capitalization of $290.84 million, a PE ratio of -4.00 and a beta of 1.86. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.55.

Hedge Funds Weigh In On Gossamer Bio

Several large investors have recently modified their holdings of the stock. Octagon Capital Advisors LP grew its position in Gossamer Bio by 99.7% during the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after purchasing an additional 9,162,117 shares during the last quarter. Alyeska Investment Group L.P. increased its position in shares of Gossamer Bio by 52.7% during the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock valued at $7,968,000 after acquiring an additional 3,041,058 shares in the last quarter. Silverarc Capital Management LLC raised its holdings in Gossamer Bio by 9.3% in the 4th quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock worth $5,583,000 after acquiring an additional 526,495 shares during the last quarter. Monaco Asset Management SAM boosted its stake in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after purchasing an additional 1,520,721 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Gossamer Bio by 14.6% in the 4th quarter. Millennium Management LLC now owns 3,586,067 shares of the company’s stock worth $3,244,000 after purchasing an additional 457,179 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.